SC-560
| SC-560 | |
|---|---|
| INN | |
| Drug class | |
| Routes of administration | |
| Pregnancy category | |
| Bioavailability | |
| Metabolism | |
| Elimination half-life | |
| Excretion | |
| Legal status | |
| CAS Number | |
| PubChem | |
| DrugBank | |
| ChemSpider | |
| KEGG | |
SC-560 is a selective cyclooxygenase-1 (COX-1) inhibitor, which is a type of nonsteroidal anti-inflammatory drug (NSAID). It is primarily used in research settings to study the role of COX-1 in various physiological and pathological processes.
Mechanism of Action[edit]
SC-560 selectively inhibits the enzyme cyclooxygenase-1 (COX-1), which is responsible for the conversion of arachidonic acid to prostaglandins. Prostaglandins are lipid compounds that have diverse roles in inflammation, pain, and fever. By inhibiting COX-1, SC-560 reduces the production of prostaglandins, thereby exerting anti-inflammatory and analgesic effects.
Pharmacokinetics[edit]
The pharmacokinetic profile of SC-560 has been studied in various animal models. It is known to have a high affinity for COX-1, with minimal activity against cyclooxygenase-2 (COX-2). This selectivity is important for understanding the differential roles of COX-1 and COX-2 in inflammation and other physiological processes.
Clinical Applications[edit]
While SC-560 is not used clinically, it serves as a valuable tool in research to delineate the specific contributions of COX-1 in various diseases. Studies have utilized SC-560 to explore its effects in models of cardiovascular disease, cancer, and neurodegenerative disorders.
Research Studies[edit]
Research involving SC-560 has provided insights into the role of COX-1 in platelet aggregation, gastric mucosal protection, and renal function. For instance, studies have shown that COX-1 inhibition by SC-560 can reduce platelet aggregation, which is a critical factor in the prevention of thrombotic events.
Safety and Toxicity[edit]
As with other NSAIDs, the use of SC-560 in research must consider potential side effects, such as gastrointestinal irritation and renal impairment. However, its selective inhibition of COX-1 may offer a different safety profile compared to non-selective NSAIDs.
